Our extensive country coverage includes:
EUROPE, MIDDLE EAST, AFRICA:
NOTE: The countries and cancers listed are specific to Epic; we are able to provide data for other countries/cancers via custom project.
Over 55 cancers (including 110+ sub-types /biomarkers) are available in to EpicOncology™:
We offer a variety of options to meet the specific needs of our clients, ranging from global access to all countries and cancers covered in EpicOncology™ to access for specific countries, cancers, and analyses.
We offer prospective clients the chance to evaluate EpicOncology™ data and online interface within a complimentary, limited access trial period. Please contact us for full details.
Access to EpicOncology™ is valid for all employees of the client and includes any updates to the database throughout the subscription period.
We present analyses data in a series of tables you can filter for stage, subtype, gender and age group. Main groupings include:
The EpicOncology™ system has the unique ability to generate specific epidemiology datasets (made available only to the client) within the EpicOncology™ interface.
A sequential treatment by any modality (i.e., surgery, radiation, and/or drug therapy); for example, first course therapy is the first time that a patient is treated, regardless of the type of treatment.
A sequential treatment within a specific modality; for example, second-line drug therapy refers to the second time that a patient receives drug therapy, though a patient might have initially been treated with surgery only, then later drug therapy (which would be 1L drug), and again drug therapy (2L drug therapy in the third-course setting).
Return of disease following a response, which could be a CR or PR; to relapse, patients must have been prior responders who survive over time, until the disease returns/relapses; it is a prevalent-based population capturing patients from prior years.
To be clear in our definitions, Epiphany refrains from using this term in our modeling. However, when used by industry to refer to patient populations, we have found that the term generally refers to relapsed disease (as defined by Epiphany) plus refractory (i.e., non-responding) patients, as usually the goal is to capture the complete pool of patients eligible for subsequent therapies. Epiphany’s model assesses both relapsed and refractory patients for possible progression. Including the refractory patients in a definition of recurrence captures all progressing patients in the definition as well.
Epiphany’s models do not use this term. In discussions, it can refer to either modality/modalities or drugs, depending on the context.
Progression refers to progression to subsequent stages of disease. In Epiphany’s models, we separate the concepts (and associated calculations) for relapse and progression. Not all patients who relapse then progress; for example, some patients may relapse in the same stage in which they received diagnosis. Metastatic patients cannot “progress” since they are already metastatic. Also, do not use the term “progression” to apply to progression between lines of therapy, as sometimes done in the industry. (Sometimes we even write out “progression-to-subsequent-stage” to clarify the concept.)
Epiphany relies on leading, publicly available cancer registries as well as registry-based datasets and secondary publications. These include:
Our promise is to provide clients with a response to, or acknowledgement of, a question within 24 hours.
Epiphany’s focus on client service is one of our primary differentiators in today’s marketplace and includes:
Yes! We offer an array of custom consulting services including specialized models based on to EpicOncology™ as well as detailed analytical support in cancer and other diseases that are not currently available in the interface. We also conduct epidemiology research, develop patient and product forecasts, and provide regulatory/HEOR support, among other related services.
Examples of projects we have completed for clients include:
Yes! Epiphany has the forecasting expertise and integrated systems to generate client specific epidemiology datasets within the EpicOncology™ interface.
Yes. Epiphany offers specialized training and presentations across a range of topics that we can deliver onsite or via webinar.